Fast Assessment of Surfactant Deficiency in Preterm Infants to Speed up Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently the investigators have developed a point of care test (LS-test) to measure surfactant as lecithin in gastric aspirates from preterm infants.

This test can be done immediately at delivery and potentially be used to guide surfactant treatment.

To obtain evidence-based knowledge on harms and benefit of surfactant therapy guided by the L/S test, a randomized clinical trial with relevant clinical short-and long-term outcomes needs to be performed, which is why the FAST 2 Trial has been designed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fast Assessment of Surfactant Deficiency in Preterm Infants to Speed up Treatment - Validation Study

NCT05615428

Surfactant Deficiency Syndrome Neonatal Respiratory Distress Syndrome in Premature Infant

COMPLETED

Fast Assessment of Surfactant Deficiency to Speed up Treatment

NCT03235882

RDS of Prematurity Prematurity

COMPLETED

Determination of Lung Maturity and Prediction of RDS at Birth

NCT02076126

RDS Premature Birth

COMPLETED

Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

NCT00599651

Respiratory Distress Syndrome, Newborn

TERMINATED NA

The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

NCT03808402

Respiratory Distress Syndrome Bronchopulmonary Dysplasia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment of respiratory distress syndrome (RDS) has evolved greatly over the past three decades. Major advances in treatment include antenatal steroids, early nasal continuous positive airway pressure (nCPAP) combined with early rescue surfactant replacement strategies such as Intubation Surfactant Extubation (INSURE) and Less Invasive Surfactant Administration (LISA), together with use of lung protective ventilation and overall reduced use of mechanical ventilation. However, RDS and bronchopulmonary dysplasia (BPD) are still major causes of mortality and morbidity in premature infants. To improve the outcome, very early treatment with surfactant is necessary. However, only about half of infants with a gestational age (GA) below 30 weeks need surfactant treatment and prophylactic surfactant treatment increases the combined mortality and incidence of BPD contrary to selective rescue surfactant treatment. Therefore, there is a need for a rapid test to guide early targeted surfactant treatment.

The investigators have recently developed a new test of lung maturity based on measuring the lecithin sphingomyelin ratio (L/S) in fresh gastric aspirates (GAS) from newborn preterm infants using mid-red Fourier Transform Infrared spectroscopy (FTIR). The sphingomyelin concentration in amniotic fluid and accordingly in GAS is relatively constant during the pregnancy, whereas the lecithin (or dipalmitoylphosphatidylcholine (DPPC), the lung surfactant phospholipid with the highest surface activity) concentration increases with the lung maturation.

It has been demonstrated in clinical observational trials that this laboratory based L/S-test predicts development of RDS when measured immediately at delivery (FAST 1 Trial).

The L/S-test has now been developed into an easy-to-use Point of Care (POC) test for bedside use that expresses the L/S ratio in approximately 10 minutes. It is believed this new POC test can be used to guide surfactant therapy, enabling very early rescue treatment, potentially even before symptoms occur.

To obtain evidence-based knowledge on harms and benefit of surfactant therapy guided by the L/S test, a randomized clinical trial with relevant clinical short-and long-term outcomes needs to be performed, which is why the FAST 2 Trial has been designed.

During design and development of the FAST 2 Trial protocol extensive engineering work has been conducted towards building a fully automated L/S POC Device (AIMI 1.0/2.0) from the prototypes in the first L/S studies (including FAST 1 Trial).

During this process the accuracy of the L/S algorithm has been improved through machine learning and use of artificial intelligence. Consequently, the previously defined cut-off ratio from the FAST 1 Trial needs to be re-validated using the L/S POC Device in a new population of preterm infants.

The FAST 2 Trial therefore consists of two individual studies starting with the FAST 2 Validation Study which will followed by the FAST 2 Randomized Clinical Trial (FAST 2 RCT) once completed. The FAST 2 Validation study has been registered separately on clinicaltrials.gov (NCT05615428).

This registration concerns the FAST 2 RCT

Participants:

Preterm newborn infants with gestational age at birth of ≤ 29+6 weeks who have not received prophylactic surfactant.

Intervention:

Surfactant treatment guided by fast determination of the L/S-ratio in a fresh gastric aspirate (GAS) obtained at birth, measured by Fourier Transform Mid-infrared Spectroscopy as a POC test.

Comparison:

Standard rescue surfactant treatment based on clinical criteria defined by the European Consensus Guidelines on the management of Respiratory Distress Syndrome

Outcome:

Infants surviving without moderate to severe BPD assessed at 36 weeks post menstrual age as per a modified NIH definition

The primary outcome is a composite of survival without moderate to severe BPD, defined as per a modified "NIH definition"

The primary objective is to compare the rate of survival without moderate to severe BPD between 2 groups:

* L/S guided treatment of surfactant deficiency with exogenous surfactant (intervention group) vs.
* Standard treatment of surfactant deficiency (comparison).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surfactant Deficiency Syndrome Neonatal Respiratory Distress Syndrome, Newborn Bronchopulmonary Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.

The GAS will be analyzed bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as "treat with surfactant" or " do not treat with surfactant" depending on wether the LS-ratio is under or above the cut-off ratio for treatment.

Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)

Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30). The LS-ratio for those infants will remain blinded

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

It is not possible to blind LS-guided surfactant treatment in the interventional group, but the actual result of the LS-test will remain blinded for both groups until completion of the study except for as detailed above.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention arm LS guided treatment

all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.

The GAS will be analyzed immediately at the bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as "treat with surfactant" or " do not treat with surfactant" depending on wether the LS-ratio is under or above the cut-off ratio for treatment.

Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30) - ie same as in control group.

Group Type EXPERIMENTAL

LS test

Intervention Type DIAGNOSTIC_TEST

If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)

Control arm - routine surfactant treatment

all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.

The GAS will be analyzed immediately at the bedside by a LS-test POC device, but result will remain blinded.

Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30). The LS-ratio for those infants will remain blinded

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LS test

If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* GA ≤ 29+6, inborn at a participating centre
* Age less than 45 minutes as GAS must be sampled within 45 minutes from delivery.

Exclusion Criteria

* Treated with surfactant before randomisation and obtaining gastric aspirates
* Diagnosis of major malformations (major congenital heart defects, congenital diaphragmatic hernia, gastroschisis/omphalocele, pulmonary abnormalities including pulmonary hypoplasia and trachea-oesophageal fistula
* Antenatal suspicion of significant oligohydramnios and lung hypoplasia
* Any intrauterine intervention except if done for genetic testing

Maximum Eligible Age

45 Minutes

Eligible Sex

ALL

Accepts Healthy Volunteers

No